Transport Proteins and Intestinal Metabolism: P-Glycoprotein and Cytochrome P4503A

Therapeutic Drug Monitoring

Volumn 26, Issue 2, 2004, Pages 104-106

  Christians, Uwe ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Cytochrome P4503A4; Intestinal metabolism; P glycoprotein

Indexed keywords

13 O NORTACROLIMUS; CARRIER PROTEIN; CELL NUCLEUS RECEPTOR; CYTOCHROME P450 3A; DRUG METABOLITE; GLYCOPROTEIN P; PROTEIN PXR; PROTEIN SXR; TACROLIMUS; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DRUG METABOLISM; DRUG UPTAKE; ENZYME ACTIVITY; ENZYME SUBSTRATE COMPLEX; HUMAN; INTESTINE ABSORPTION; INTESTINE CELL; INTESTINE VILLUS; LIVER METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL TRANSPORT, ACTIVE; CYTOCHROME P-450 CYP3A; INTESTINAL MUCOSA; INTESTINES; OXIDOREDUCTASES, N-DEMETHYLATING; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS;

EID: 11144221888     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200404000-00002     Document Type: Conference Paper

References (12)

1. Cummins CL, Jacobsen W, Benet LZ. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther. 2002;300:1036-1045.
2. Benet LZ, Cummins CL, Wu CY. Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab. 2003;4:393-398.
3. Benet LZ, Cummins CL. The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev. 2001;50(suppl 1):S3-S11.
4. Wacher J, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P4503A and P-glycoprotein: implications for drug delivery and cancer chemotherapy. Mol Carcinogen. 1995;13:129-134.
5. Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nature Med. 2001;7:584-590.
6. Geick AW, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001;276:14581-14587.
7. Iber H, Sewer MB, Barclay TB, et al. Modulation of drug metabolism in infectious and inflammatory diseases. Drug Metab Rev. 1999;31:29-41.
8. Sukhai M, Piquette-Miller M. Regulation of the multidrug resistance genes by stress signals. J Pharm Pharmaceut Sci. 2000;3:268-280.
9. Christians U, Spiekermann K, Schottmann R, et al. Cyclosporin metabolite patterns in blood from patients with acute graft versus host disease after bone marrow transplantation. Bone Marrow Transplant. 1993;12:27-33.
10. Lampen A, Christians U, Gonschior AK, et al. Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber. Br J Pharmacol. 1996;117:1730-1734.
11. Soldner A, Benet LZ, Mutschler E, et al. Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDRI and Caco-2 cell monolayers. Br J Pharmacol. 2000;129:1235-1243.
12. CDER, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research (CBER). Guidancefor the Industry. Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies In Vitro. April 1997 (www.fda.gov/cder/guidance)